title: Moxifloxacin (Avelox) for the treatment of bacterial skin infections.
abstract: Moxifloxacin (Avelox, Bayer), which is available for oral administration, is a broad-spectrum synthetic antimicrobial agent with excellent Gram-positive activity and good Gram-negative activity. The US FDA recently approved this drug for the treatment of bacterial skin infections.
authors.affiliation: Departments of Dermatology and Cutaneous Biology, Jefferson Medical Colege, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
authors.forename: L C
authors.initials: LC
authors.lastname: Parish
authors.forename: J A
authors.initials: JA
authors.lastname: Witkowski
authors.forename: H B
authors.initials: HB
authors.lastname: Routh
mesh_terms: D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001372:Aza Compounds; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D011804:Quinolines; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin